June 8, 2017August 24, 2022
Keytruda Improves Survival in Advanced Melanoma Patients Compared to Yervoy, Phase 3 Trial Shows
News
Patients with unresectable or metastatic melanoma who were treated with Keytruda (pembrolizumab) in a pivotal clinical trial showed superior and sustained time ... Read more
June 6, 2017
New Evidence Presented on Accuracy of DecisionDx-Melanoma Prognosis Test
News
Castle Biosciences presented three abstracts on the validity of using its 31-Gene Expression Profile (GEP) Test for melanoma prognosis at the ... Read more
June 1, 2017June 2, 2017
Biothera to Present Detailed Design of Combo Therapy Study for Melanoma, Breast Cancer
News
Biothera Pharmaceuticals will present the detailed study design of the IMPRIME-1 clinical trial at the upcoming 2017 ASCO Annual Meeting June 2-6 in ... Read more
May 30, 2017
Researchers Provide New Insights into Melanoma Immune Resistance
News
A new study presents detailed information into the processes used by cancer cells to evade and resist the immune response. Researchers studied ... Read more
May 25, 2017May 25, 2017
New Clinical Trial Underway for Treatment of Advanced Melanoma
News
A new clinical trial is underway assessing the addition of the first-in-class AXL kinase inhibitor, BGB324, to standard of care treatment for patients with ... Read more
May 23, 2017May 23, 2017
Skin Cancer Awareness Month Brings Sun Safety to Schools
News
Educating people of all ages, particularly children, about the dangers of sun exposure is urgent to preventing the increased prevalence ... Read more
May 18, 2017
First Patient Enrolled in ONCOS-102, Keytruda Combo Trial for Advanced Melanoma
News
The first patient has been enrolled in Targovax‘s pilot clinical trial for advanced or unresectable melanoma patients whose cancer progressed after treatment ... Read more
May 16, 2017
ImmunoPulse IL-12 and Keytruda Combo Therapy to be Tested in Phase 2 Trial
News
The combination of ImmunoPulse IL-12 and the anti-PD-1 therapy Keytruda (pembrolizumab) soon will be tested in a Phase 2 trial for treatment ... Read more
May 11, 2017
Binimetinib Improves Progression-free Survival of Certain Melanoma Patients in Phase 3 Trial
News
Adding the small molecule MEK inhibitor binimetinib to the BRAF inhibitor encorafenib was safe and significantly prolonged the time to disease progression ... Read more
May 9, 2017May 9, 2017
Melanoma Scientist Among 6 in NYC Awarded Prestigious Research Prize
News
The Pershing Square Sohn Cancer Research Alliance has announced the six winners of the fourth edition of the annual Pershing ... Read more
May 4, 2017
Castle’s Gene Test Shows Accuracy in Predicting Recurrence, Spread of Head and Neck Melanoma
News
Castle Biosciences’ DecisionDx-Melanoma test can be used to accurately predict cancer recurrence and metastasis in patients with head and neck melanoma, ... Read more
April 25, 2017
IMP321, Keytruda Combo Trial Receives OK to Open Last Patient Group
News
Prima Biomed, an Australian biotechnology company developing immunotherapies for cancer and autoimmune diseases, announced it has received approval for the ... Read more

January 7, 2016January 7, 2016

Skin Substitute for Rare Congenital Condition Seeks Special FDA Recognition

News

Amarantus BioScience Holdings, Inc., announced it has requested Rare Pediatric Disease Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) to use its Engineered Skin Substitute (ESS) as a potential treatment ... Read more

January 5, 2016May 17, 2016

Amgen’s IMLYGIC Approved by the European Commission To Treat Metastatic Melanoma Patients

News

Amgen’s IMLYGIC (talimogene laherparepvec) is the first oncolytic immunotherapy to show evidence of therapeutic benefit in patients with metastatic melanoma in a Phase III clinical trial. As a result, the ... Read more

December 17, 2015December 17, 2015

New Melanoma Drug Shows Promise in Resistant and Unresponsive Cancers

News

Sanford Burnham Prebys Medical Discovery Institute (SBP) researchers discovered a new drug, SBI-756, which inhibits melanoma cell growth in vitro, and delays disease onset and reduces the incidence of melanoma in ... Read more

December 15, 2015December 15, 2015

Rare Sugar L-Fucose May Help Block Tumor and Metastasis Growth

News

New research suggests that a rare sugar found in seaweed, mushrooms, seeds, and other foods may be helpful when treating skin cancer. The L-fucose sugar has been formerly associated with a ... Read more

December 10, 2015December 10, 2015

Metastatic Melanoma Immunotherapy Shows Promise in Mice Study

News

Memgen LLC, a company that develops cancer immunotherapies, presented positive preclinical data for its main immuno-oncology drug, ISF35, during the 30th annual meeting of the Society of Immunotherapy of Cancer (SITC), ... Read more

December 4, 2015December 3, 2015

Array, Pierre Fabre to Collaborate on New Melanoma Drugs

News

Array BioPharma Inc., based in Colorado, and Pierre Fabre of France have recently announced they will collaborate on the development and commercialization of novel oncology products for the treatment of melanoma and ovarian ... Read more

December 3, 2015December 3, 2015

Amgen Pressing Forward with Promising Melanoma Therapy

News

Amgen recently presented additional results from the company’s Phase 3 clinical trial of Imlygic (talimogene laherparepvec) as a monotherapy for the treatment of metastatic melanoma, as well as new results from its ongoing ... Read more

November 12, 2015November 12, 2015

Roche’s New Melanoma Drug, Cotellic, Gets FDA Approval

News

Roche recently announced that the U.S. Food and Drug Administration (FDA) approved Cotellic (cobimetinib) used in combination with Zelboraf (vemurafenib) for the treatment of patients with BRAF V600E or V600K mutation-positive unresectable ... Read more

November 10, 2015November 12, 2015

New Metastatic Melanoma Treatment from Caladrius Shows Promise

News

Caladrius Biosciences, Inc., recently presented novel data at the 2015 Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which took place in Baltimore, Maryland, Nov. 4-8, 2015. The clinical and ... Read more

November 5, 2015November 5, 2015

IMLYGIC, an Unresectable Melanoma Treatment, Gets Positive CHMP Opinion

News

Amgen announced that the Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), has given a positive recommendation for IMLYGIC (talimogene laherparepvec) as a treatment for adult ... Read more

November 5, 2015November 5, 2015

La Roche-Posay Promotes ‘SOS-Save Our Skin’ Program for 5th Year

News

La Roche-Posay, a global leader in ultraviolet (UV) protection, is continuing its work to increase public awareness of skin cancer and prevention with its SOS – Save our Skin Campaign, now in ... Read more

October 22, 2015October 22, 2015

For Treatment-Naive Melanoma Patients, Nivolumab May Hold Added Benefit

News

According to a recently released collection of papers (dossier) by the Institute for Quality and Efficiency in Health Care (IQWiG), use of the drug Nivolumab (trade name: Opdivo) may be ... Read more

Keytruda Improves Survival in Advanced Melanoma Patients Compared to Yervoy, Phase 3 Trial Shows

New Evidence Presented on Accuracy of DecisionDx-Melanoma Prognosis Test

Biothera to Present Detailed Design of Combo Therapy Study for Melanoma, Breast Cancer

Researchers Provide New Insights into Melanoma Immune Resistance

New Clinical Trial Underway for Treatment of Advanced Melanoma

Skin Cancer Awareness Month Brings Sun Safety to Schools

First Patient Enrolled in ONCOS-102, Keytruda Combo Trial for Advanced Melanoma

ImmunoPulse IL-12 and Keytruda Combo Therapy to be Tested in Phase 2 Trial

Binimetinib Improves Progression-free Survival of Certain Melanoma Patients in Phase 3 Trial

Melanoma Scientist Among 6 in NYC Awarded Prestigious Research Prize

Castle’s Gene Test Shows Accuracy in Predicting Recurrence, Spread of Head and Neck Melanoma

IMP321, Keytruda Combo Trial Receives OK to Open Last Patient Group